Drug Profile


Alternative Names: AB-SA01; AmpliPhage-002

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation; United States Army Medical Research and Materiel Command; University of Adelaide
  • Class Antibacterials; Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Staphylococcal infections

Most Recent Events

  • 19 Mar 2018 AmpliPhi Biosciences Corporation collaborates with the Western Sydney Local Health District and the Westmead Institute for Medical Research on an expanded access programme of AB SA01 for Staphylococcal infections
  • 19 Mar 2018 AmpliPhi Biosciences Corporation intends to submit data from an expanded access programme to the US FDA in mid-2018 to obtain feedback on the path to regulatory approval for AB SA01 in Staphylococcal infections
  • 13 Mar 2018 AmpliPhi Biosciences Corporation establishes CRADA with Department of Veterans Affairs for expanded access of AB SA01 in Staphylococcal infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top